DIVERSA TECHNOLOGIES SL

DIVERSA positions itself as a strategic technology‑enabling partner for pharma and biotech companies developing RNA and biomolecule‑based therapeutics in indications where delivery is the primary bottleneck. The company collaborates closely with partners to address delivery challenges across the development continuum, supporting the optimization of formulation, localization, reproducibility and translational robustness of assets. Designed for challenging tissue environments where conventional systems struggle, DIVERSA’s patented Sphingolipid Nanoparticle (SNP) and Sphingolipid Nanoemulsion (SN) platforms deliver both technical differentiation and a strong, defensible Freedom to Operate (FTO), offering partners a strategically clean alternative to the densely patented LNP landscape. This positioning enables pharma and biotech companies to advance high‑value RNA  and biotechnology programs with reduced IP risk, lower dependency on third‑party platforms and greater flexibility in co‑development, licensing and long‑term pipeline strategy.